<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136135">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01853280</url>
  </required_header>
  <id_info>
    <org_study_id>2012-P-000379</org_study_id>
    <nct_id>NCT01853280</nct_id>
  </id_info>
  <brief_title>L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults</brief_title>
  <official_title>L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pamlab, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study seeks to evaluate initial evidence for efficacy and tolerability of
      L-methylfolate supplementation to OROS-Methylphenidate pharmacotherapy in treating Attention
      Deficit Hyperactivity Disorder (ADHD) and associated symptoms in adults with ADHD. The
      investigators will conduct a 12-week double-blind randomized placebo-controlled trial with
      L-methylfolate supplementing open-label OROS-Methylphenidate (OROS-MPH) treatment. The
      investigators propose to examine 40 adult (ages 18-55) subjects satisfying the DSM-IV
      diagnostic criteria for ADHD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adult ADHD Investigator Symptom Rating Scale</measure>
    <time_frame>Assessed at each visit from baseline to study completion (12 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Each of the individual DSM-IV symptoms of ADHD is rated 0 to 3 on a scale of severity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>L-Methylfolate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg of L-Methylfolate (Deplin®) daily for 12 weeks as a supplement to OROS-Methylphenidate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (for L-Methylfolate)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>15 mg matched placebo comparator, with open-label OROS-Methylphenidate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-methylfolate</intervention_name>
    <description>15mg/day L-methylfolate.</description>
    <arm_group_label>L-Methylfolate</arm_group_label>
    <other_name>Deplin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OROS-Methylphenidate</intervention_name>
    <description>All subjects will be treated with open-label OROS-MPH</description>
    <arm_group_label>L-Methylfolate</arm_group_label>
    <arm_group_label>Placebo (for L-Methylfolate)</arm_group_label>
    <other_name>Concerta®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adults ages 18-55 years of age.

          2. A diagnosis of childhood onset ADHD, meeting all but the age of onset criteria
             according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth
             Edition (DSM-IV),  based on clinical assessment.  Childhood onset will be defined
             according to established research criteria, requiring onset of two symptoms of
             inattentive or of impulsive/hyperactive traits by the age of 12 22.

          3. A score of 24 or more on the Adult ADHD Investigator Symptom Report Scale (AISRS).

        Exclusion Criteria:

          1. A history of non-response or intolerance to methylphenidate at adequate doses as
             determined by the clinician.

          2. A history of intolerance to L-methylfolate supplementation.

          3. Pregnant or nursing females.

          4. Serious, unstable medical illness including hepatic, renal, gastroenterological,
             respiratory, cardiovascular, endocrinologic (thyroid), neurologic (seizure),
             immunologic, or hematologic disease.

          5. Glaucoma.

          6. Clinically unstable psychiatric conditions including suicidality, homicidality,
             bipolar disorder, psychosis, history of or current marked anxiety, tension or
             agitation potentially exacerbated by a stimulant, or lifetime history of any other
             clinically serious condition potentially exacerbated by a stimulant, such as mania or
             psychosis.

          7. Tics or a family history or diagnosis of Tourette's syndrome.

          8. Current (within 3 months) DSM-IV criteria for abuse or dependence with any
             psychoactive substance other than nicotine.

          9. Multiple adverse drug reactions.

         10. Any other concomitant medication with primarily central nervous system activity other
             than specified in Concomitant Medication portion of the protocol.

         11. Current use of MAO Inhibitor or use within the past two weeks.

         12. Investigator and his/her immediate family; defined as the investigator's spouse,
             parent, child, grandparent, or grandchild.

         13. Use of supplemental folic acid greater than 400 mcg per day, L-methylfolate, or
             Omega-3 Fatty Acids greater than 800 mcg per day within two weeks prior to the
             baseline study visit.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rebecca Grossman, B.A.</last_name>
    <phone>617-643-1432</phone>
    <email>rgrossman1@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Grossman</last_name>
      <phone>617-643-1432</phone>
      <email>rgrossman1@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Craig B Surman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Craig B. Surman, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <keyword>Deplin</keyword>
  <keyword>L-methylfolate</keyword>
  <keyword>Natural Treatments</keyword>
  <keyword>Medical Food</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
